الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Thrombocytopenia is defined as a platelet count below 150,000/μL. It is the most common hematological complication in patients with chronic liver disease (CLD).The prevalence of thrombocytopenia in chronic liver diseases ranges from 6 % among non-cirrhotic patients with chronic liver disease to 70 % among patients with liver cirrhosis (Khalil et al., 2019).
The pathophysiology is multifactorial. Portal hyper-tension leads to splenomegaly and then splenic sequestration of platelets. In addition, thrombopoietin levels in patients with chronic liver disease are low, leading to decreased production of platelets. The combination of increased sequestration and decreased production leads to low platelet counts, which tend to correlate with both the degree of portal hypertension as well as with the degree of liver dysfunction. In other words, the more liver dysfunction, the lower the thrombopoietin levels, and also the more portal hypertension patients tend to have, which leads to progressive thrombocytopenia (Brown, 2019).
The aim of this study is to investigate the association between thrombocytopenia and the risk of higher mortality incidence in hepatic patients in intensive care unit.
Our study revealed that patients with lower platelet counts had significantly higher risk of death and ICU stay.
In our study we showed that there are two independent risk factors affecting the outcome of hepatic patients in the ICU they were thrombocytopenia and high APACHE score.
These observations highlight the potential importance of low platelets count in identifying a group of hepatic patients who are at risk for poorer prognosis.
So, measurement of platelets count could be good predictor for early prediction of ICU outcomes of hepatic patients.
The association between platelets count and long term patient survival in CLD patients has not been reported obviously and need further studies.